Find a Researcher
Fredric Manfredsson, PhD
Gene Therapy, Parkinson's
Fredric Manfredsson, PhD, is an associate professor in the Department of Translational Neuroscience at Barrow Neurological Institute.
Dr. Manfredsson’s expertise includes microbiology and virology, with a special interest in gene therapy for Parkinson’s disease and other neurodegenerative diseases. He is a member of the American Society for Gene & Cell Therapy, The American Society for Neural Therapy and Repair, and the Society for Neuroscience.
Dr. Manfredsson earned his doctorate degree in neuroscience from the University of Florida in Gainesville, where he also completed a postdoctoral fellowship in neuroscience.
Dr. Manfredsson’s research has multiple focuses. One aspect is to better understand the role of the protein alpha-synuclein in both healthy cells and those affected by Parkinson’s disease. His research also emphasizes understanding the symptomology of the disease, with a focus on the treatment of levodopa-induced dyskinesia and nonmotor symptoms experienced by nearly all patients with Parkinson’s disease.
- Postdoctoral Fellowship, University of Florida, Department of Neuroscience, 2006-2010
- PhD, University of Florida, Graduate Program in Biomedical Sciences, Neuroscience, 2006
- BS, Arizona State University, Microbiology, 1999
- President, American Society for Neural Therapy and Repair, 2018-2020
- Fellow, American Society for Neural Therapy and Repair, 2015-Present
- Cover Image, Molecular Therapy, June 2009, March 2015
- Julius Axelrod Travel Award, Society for Neuroscience, 2011
- Alumni Fellowship, University of Florida, 2001-2005
- American Society for Gene & Cell Therapy
- The American Society for Neural Therapy and Repair
- Society for Neuroscience
Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs
Date: 10/2023
Authors: Ella A. Kasanga, Yoonhee Han, Marla K. Shifflet, Walter Navarrete, Robert McManus, Caleb Parry, Arturo Barahona, Vicki A. Nejtek, Fredric P. Manfredsson, Jeffrey H. Kordower, Jason R. Richardson, Michael F. Salvatore
Downregulation of striatal Ca1.3 inhibits the escalation of levodopa-induced dyskinesia in male and female parkinsonian rats of advanced age
Date: 06/2023
Authors: Margaret E. Caulfield, Molly J. Vander Werp, Jennifer A. Stancati, Timothy J. Collier, Caryl E. Sortwell, Ivette M. Sandoval, Fredric P. Manfredsson, F P Manfredsson, Kathy Steece-Collier
Differential expression of RET and GDNF family receptor, GFR-α1, between striatum and substantia nigra following nigrostriatal lesion: A case for diminished GDNF-signaling
Date: 05/2023
Authors: Ella A. Kasanga, Yoonhee Han, Walter Navarrete, Robert McManus, Marla K. Shifflet, Caleb Parry, Arturo Barahona, Fredric P. Manfredsson, F P Manfredsson, Vicki A. Nejtek, Jason R. Richardson, Michael F. Salvatore
Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia
Date: 03/2023
Authors: Carla Budrow, Kayla Elder, Michael Coyle, Ashley Centner, Natalie Lipari, Sophie Cohen, John Glinski, N'Senga Kinzonzi, Emily Wheelis, Grace McManus, Fredric Manfredsson, F P Manfredsson, Fredric P. Manfredsson, Christopher Bishop
Nicotine-Mediated Recruitment of GABAergic Neurons to a Dopaminergic Phenotype Attenuates Motor Deficits in an Alpha-Synuclein Parkinson's Model
Date: 02/2023
Authors: Jessica IChi Lai, Alessandra Porcu, Benedetto Romoli, Maria Keisler, Fredric P. Manfredsson, F P Manfredsson, Susan B. Powell, Davide Dulcis
Fredric Manfredsson, PhD
Gene Therapy, Parkinson's
Fredric Manfredsson, PhD, is an associate professor in the Department of Translational Neuroscience at Barrow Neurological Institute.
Dr. Manfredsson’s expertise includes microbiology and virology, with a special interest in gene therapy for Parkinson’s disease and other neurodegenerative diseases. He is a member of the American Society for Gene & Cell Therapy, The American Society for Neural Therapy and Repair, and the Society for Neuroscience.
Dr. Manfredsson earned his doctorate degree in neuroscience from the University of Florida in Gainesville, where he also completed a postdoctoral fellowship in neuroscience.
Dr. Manfredsson’s research has multiple focuses. One aspect is to better understand the role of the protein alpha-synuclein in both healthy cells and those affected by Parkinson’s disease. His research also emphasizes understanding the symptomology of the disease, with a focus on the treatment of levodopa-induced dyskinesia and nonmotor symptoms experienced by nearly all patients with Parkinson’s disease.
- Postdoctoral Fellowship, University of Florida, Department of Neuroscience, 2006-2010
- PhD, University of Florida, Graduate Program in Biomedical Sciences, Neuroscience, 2006
- BS, Arizona State University, Microbiology, 1999
- President, American Society for Neural Therapy and Repair, 2018-2020
- Fellow, American Society for Neural Therapy and Repair, 2015-Present
- Cover Image, Molecular Therapy, June 2009, March 2015
- Julius Axelrod Travel Award, Society for Neuroscience, 2011
- Alumni Fellowship, University of Florida, 2001-2005
- American Society for Gene & Cell Therapy
- The American Society for Neural Therapy and Repair
- Society for Neuroscience
Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs
Date: 10/2023
Authors: Ella A. Kasanga, Yoonhee Han, Marla K. Shifflet, Walter Navarrete, Robert McManus, Caleb Parry, Arturo Barahona, Vicki A. Nejtek, Fredric P. Manfredsson, Jeffrey H. Kordower, Jason R. Richardson, Michael F. Salvatore
Downregulation of striatal Ca1.3 inhibits the escalation of levodopa-induced dyskinesia in male and female parkinsonian rats of advanced age
Date: 06/2023
Authors: Margaret E. Caulfield, Molly J. Vander Werp, Jennifer A. Stancati, Timothy J. Collier, Caryl E. Sortwell, Ivette M. Sandoval, Fredric P. Manfredsson, F P Manfredsson, Kathy Steece-Collier
Differential expression of RET and GDNF family receptor, GFR-α1, between striatum and substantia nigra following nigrostriatal lesion: A case for diminished GDNF-signaling
Date: 05/2023
Authors: Ella A. Kasanga, Yoonhee Han, Walter Navarrete, Robert McManus, Marla K. Shifflet, Caleb Parry, Arturo Barahona, Fredric P. Manfredsson, F P Manfredsson, Vicki A. Nejtek, Jason R. Richardson, Michael F. Salvatore
Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia
Date: 03/2023
Authors: Carla Budrow, Kayla Elder, Michael Coyle, Ashley Centner, Natalie Lipari, Sophie Cohen, John Glinski, N'Senga Kinzonzi, Emily Wheelis, Grace McManus, Fredric Manfredsson, F P Manfredsson, Fredric P. Manfredsson, Christopher Bishop
Nicotine-Mediated Recruitment of GABAergic Neurons to a Dopaminergic Phenotype Attenuates Motor Deficits in an Alpha-Synuclein Parkinson's Model
Date: 02/2023
Authors: Jessica IChi Lai, Alessandra Porcu, Benedetto Romoli, Maria Keisler, Fredric P. Manfredsson, F P Manfredsson, Susan B. Powell, Davide Dulcis